The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Study reveals VLCFA metabolism as a key target in multiple myeloma, enhancing drug efficacy and overcoming resistance.

Multiple sclerosis (MS) is one of the most widespread disabling neurological conditions of young adults around the world. It affects almost 1 million people in the United States, and about 2.9 ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...

He previously worked at Android Police and Tech Advisor. Google’s AI assistant Gemini is now able to carry out tasks across multiple apps in a single interaction, in an update announced today ...

Recovery from multiple myeloma leads to a renewed sense of purpose and determination, with hope found in small victories. The Bells of Hope community provides support and inspiration, fostering unity ...

“[Multiple myeloma] has not been considered curable ... a portfolio it scooped up in its $74 billion buyout of Celgene in 2019. It also markets Empliciti, a monoclonal antibody developed with AbbVie.

the future of myeloma therapy will involve genotyping of individual patient tumors, and designing therapy based on the results. Therapy will become bespoke, targeting the multiple deregulated ...

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory drugs achieved an overall response rate of 56.2% and median progression ...